原始出處紀錄
決策級主要結果 (Topline)
Verastem：RAMP 301 第三期初步數據預計於 2027 年年中公布
公司簡報指出，RAMP 301 確證性第三期試驗將比較 avutometinib + defactinib 與研究者選擇療法，用於復發性 LGSOC 患者，預計於 2027 年年中公布初步數據。此數據旨在確認 RAMP 201 在 KRAS 突變患者中的結果，並可能將核准適應症擴大至所有 KRAS 突變狀態。
關鍵事實
- 申報時間
- 2026年1月8日 下午09:16
- 事件
- 主要結果 (Topline)
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 tm262531d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026 2 FORWARD - LOOKING STATEMENTS This presentation includes forward - looking statements about, among other things, Verastem Oncology’s (the “Company”) programs an d product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJACO - PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with K irsten rat sarcoma viral oncogene homolog (KRAS) mutant - type (mt) recurrent Low - Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc. (GenFlee